Search Results for “cancer” – Page 61 – media

The second day of the 2024 National Negotiations | Hengrui, CSPC Pharmaceutical, Qilu Pharmaceutical, AstraZeneca…appeared! Antidiabetic and tumor drugs may be the focus

The 2024 National Medical Insurance Negotiations entered the second day. Beijing was sunny. On this day, antidiabetic and tumor drugs were the highlights. On the second day of the National Negotiations, Huang Bin, Vice President of AstraZeneca China, and Xia Yu, founder, chairman, president and CEO of Kangfang Bio, appeared at the National Negotiations. On the morning of October 28, the companies participating in the negotiations included AstraZeneca, Hengrui, Xinlitai, Hisun, CSPC Pharmaceutical, etc.; in the afternoon, Zhejiang Jingxin Pharmaceutical, Union Qilin, Beijing Novartis, Luye Pharmaceutical, Jiangsu Hausen, Bristol-Myers Squibb, Qilu, Changchun Jinsai, Zejing Bio, Hengrui, Novo Nordisk, etc. were present. Some on-site observers said that anti-tumor, antidiabetic and other chronic disease drugs were the protagonists of the second day of the National Negotiations. The National Medical Insurance Administration has carried out adjustments to the medical insurance drug list for six consecutive years, adding a total of 744 drugs to ...
- Source: drugdu
- 41
- October 30, 2024
Endoscopic equipment company completes over 100 million yuan Series B financing

Recently, Shenzhen Xingchen Sea Medical Technology Co., Ltd. (hereinafter referred to as “Xingchen Sea Medical”) announced the completion of a Series B financing of over 100 million yuan, led by Yuansheng Venture Capital, with continued investment from old shareholders Junlian Capital and Daotong Investment, and Haoyue Capital serving as the exclusive financial advisor. It is reported that this round of financing will help Xingchen Hai Medical further expand its production capacity, accelerate new product research and development, and expand its global market, promoting its rapid development in the field of disposable endoscopes. Complete 4 rounds of financing Xingchen Sea Medical was established in October 2020, with a founding team from domestic and foreign head medical device companies. With over ten years of experience in minimally invasive surgical product research and development, global marketing, and production management, we are committed to becoming an innovative leader in endoscopic intervention diagnosis and treatment. ...
- Source: drugdu
- 49
- October 29, 2024
High level introduction of anti-tumor adjuvant drugs! Sinopharm International negotiates and signs contracts with Korean and American pharmaceutical companies

The neutropenia caused by tumor chemotherapy can easily lead to potentially life-threatening complications. The Rolontis product treatment plan can effectively prevent and treat chemotherapy-induced neutropenia, helping cancer patients with treatment and recovery. Sinopharm International adheres to the functional mission of serving the national strategy and promoting people’s health and well-being. It leverages the role of Sinopharm Group’s international business strategy platform for pharmaceutical and health, introduces Rolontis products from South Korea, improves the safety and effectiveness of cancer patient treatment, and promotes the optimization and upgrading of the pharmaceutical and health supply chain industry chain.On October 24th, China Pharmaceutical Foreign Trade Co., Ltd., a subsidiary of Sinopharm International, and Hanmei Pharmaceutical Co., Ltd. signed a Rolontis product cooperation agreement, marking a new chapter of cooperation in the field of biomedicine based on pharmacy equipment cooperation between the two parties. Zhou Song, Secretary of the Party Committee and Chairman of Sinopharm ...
- Source: drugdu
- 39
- October 29, 2024
BeiGene PD-1 issues first prescription in the United States, opens new chapter with its own international solid tumor commercialization team

In late October, BeiGene’s self-developed PD-1 inhibitor, Trastuzumab (English trade name: TEVIMBRA), was launched ®， Chinese product name: Baize An ®） The first prescription was issued in the United States, officially entering the American market and bringing new treatment options to local patients. This milestone also marks the beginning of a new chapter for BeiGene’s own commercialization team for solid tumors in the United States.Teralizumab was approved by the US Food and Drug Administration (FDA) in March 2024 for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received systemic chemotherapy (excluding PD-1/L1 inhibitors). In October 2024, BeiGene announced the commercial launch of Trastuzumab in the United States, benefiting this patient population at a price 10% lower than other PD-1 therapies approved for this indication. The first prescription of Trastuzumab in the United States has become another important milestone in the company’s ...
- Source: drugdu
- 41
- October 29, 2024
Are stem cells the “terminator” of diabetes? Chinese scientists used stem cell regeneration therapy to cure type 1 diabetes for the first time

Cell, an international authoritative scientific journal, recently published a pioneering achievement from multiple research teams in China – the first time to use stem cell regeneration therapy to functionally cure type 1 diabetes. The research team used chemical reprogramming technology to induce pluripotent stem cells to prepare islet cells, and transplanted them to a type 1 diabetes patient, achieving clinical functional cure effect. So, how is it successful to induce stem cells to prepare pancreatic islet cells? Is functional cure truly a cure? Will stem cell technology be the key to conquer diabetes in the future? What is the difference between functional cure and cure Diabetes is a thorny disease, and its biggest harm to patients is that there are many clinical complications, which may lead to cardiovascular disease, nervous system damage, kidney disease, eye disease, foot disease, and so on. Diabetes ranks ninth among the world’s ten leading ...
- Source: drugdu
- 69
- October 28, 2024
AI+macrocyclic drug development | Circle Pharma completes $90 million Series D financing

On September 3, 2024, Circle Pharma, a biopharmaceutical company dedicated to discovering and developing cell permeable macrocycles as a clinical stage of a new therapy, announced the successful completion of $90 million in Series D funding, including the conversion of a convertible note.This round of financing is led by The Column Group, with new and old investors including Nextech Invest and Euclidean Capital participating. The funds raised from the financing will be used for the clinical development of Circle Pharma’s first and only similar cyclin A/B RxL inhibitor CID-078, and to support the development of the discovery project portfolio established by the company using its MXMO macrocycle platform. David Earp, CEO and Juris Doctor of Circle Pharma, said, “We are very grateful for the continued support of such a strong investor as we advance our pioneering work on macrocyclic therapy. This financing not only allows us to advance the clinical ...
- Source: drugdu
- 69
- October 28, 2024
Eight commonly used immune cell therapies open up a new era of healthcare

Introduction: The era of chemotherapy cannot solve the “pain points” of relapsed and refractory diffuse large B-cell lymphoma, but the era of new cell drugs has solved them. And this new cellular drug, CAR-T cell therapy, which has become a hot topic in recent years, has opened up a new era of medical treatment, with a market size of trillions of dollars. Immune cell therapy aims to enhance the immune system’s ability to fight cancer. Manufacturing cell therapy requires collecting a specific set of cells from the blood, modifying them to produce more powerful attacks on the patient’s cancer cells, and then re injecting them into the patient’s body. At present, many types of cancer cell therapies are being explored, including CAR-T cells, other genetically modified T cells, tumor infiltrating lymphocytes (TIL), NK cells, CIK cells, B cells, etc. Extracting immune cells from patients’ bodies and modifying them to make ...
- Source: drugdu
- 47
- October 26, 2024
Fosun Pharma’s Global Innovation Journey

From November 5 to 10, 2024, the 7th China International Import Expo (hereinafter referred to as “CIIE”) will be held in Shanghai. This year marks the 30th anniversary of the founding of Fosun Pharma. As a “full-time student” of the 7th CIIE, Fosun Pharma will continue to work with global partners in the Medical Devices and Healthcare Exhibition Area of Hall 7.1 (Booth No.: 7.1B3-02) to demonstrate its strong strength and far-reaching influence in becoming a global leading medical innovation integrator. Wu Yifang, Chairman of Fosun Pharma, said: “Over the past 30 years, Fosun Pharma has always insisted on innovation-driven development, actively embraced globalization, and deepened international cooperation. We are in sync with the development of the pharmaceutical industry and have demonstrated our innovative achievements and global strategic layout through the CIIE, an important platform for open cooperation. We will continue to promote global operations, accelerate the transformation of source ...
- Source: drugdu
- 46
- October 26, 2024
GE Healthcare launches its first CT production line in the country

Recently, GE Healthcare launched its first CT production line in France, marking a significant expansion of the company’s business at its Booker factory in the Yvelines department of France. It is reported that the new production line was announced in 2023 with the aim of improving the company’s agility, reducing carbon emissions, and better serving European customers. At present, the first scanner assembled in France, the Revolution Maxima CT, has been installed in the emergency department of Montargis Hospital Center in Loiret. The assembly of Revolution Maxima CT at Buc factory includes all functions and X-ray testing, system configuration, and direct delivery to European customers, which helps simplify the supply chain. It is understood that the new production line is part of GE Healthcare’s “In Europe for Europe” program, which is expected to reduce carbon emissions related to scanner transportation in Europe by 84%. This reduction is mainly due to ...
- Source: drugdu
- 66
- October 24, 2024
When Hengrui Medicine “gave up” going overseas independently

Going overseas is not only a dream, but also a big adventure that Hengrui Medicine has to take. Even under the new measurement standards, there is such a voice that the success of going overseas will be the key to determining whether Hengrui Medicine can maintain its “number one” status. Indeed, Hengrui Medicine, which has accelerated its innovation transformation, has come to a crossroads. First, relying on the domestic market in the past, Hengrui Medicine may not be in a hurry to layout overseas markets. However, with the involution of domestic innovative drugs and pharmaceutical companies going overseas to find incremental growth, internationalization has also been raised to a more important level. Although Hengrui Medicine proposed the direction of “internationalization” as early as in its 2020 annual report, its internationalization has not been smooth in the past few years. Secondly, carrelizumab has already fallen behind, and the internationalization of PD-1 ...
- Source: drugdu
- 50
- October 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.